In OSCC correlates with progression [88,89] and with relapse in children with B-lineage acute lymphoblastic leukemia (ALL) [90], but not with response to treatment [91] and in patients with non-Hodgkin’s lymphoma [92] and diffuse large B cell lymphoma, TNFα is useful to differentiate risk groups [93]. This evidence concerns the gene TNF and non-Hodgkin lymphoma.